Compositions and methods for treating influenza
The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin.
1. An immunogenic composition comprising:
a peptide comprising the amino acid sequence of SEQ ID NO: 6;
a mixture of peptides comprising peptides that comprise all 16 of the amino acid sequences defined by SEQ ID NOs: 87-102; and
a peptide comprising the amino acid sequence of SEQ ID NO: 8.
2. An immunogenic composition comprising:
a peptide comprising the amino acid sequence of SEQ ID NO: 6;
a mixture of peptides comprising peptides that comprise all 16 of the amino acid sequences defined by SEQ ID NOs. 87-102;
a peptide comprising the amino acid sequence of SEQ ID NO. 12;
a peptide comprising the amino acid sequence of SEQ ID NO. 13; and
a mixture of peptides comprising peptides that comprise all 16 of the amino acid sequences defined by SEQ ID NOs: 103-118.
3. The composition of claim 1 , wherein each peptide is immunogenic.
4. The composition of claim 1 , wherein the composition further comprises an adjuvant.
5. The composition of claim 1 , wherein at least one peptide is associated with a vesicle.
6. The composition of claim 5 , wherein the vesicle comprises a non-ionic surfactant.
7. The composition of claim 6 , wherein the vesicle comprises a transport enhancer which facilitates the transport of lipid-like molecules across mucosal membranes.
8. A method of inducing an immune response in an individual, the method comprising administering to the individual a therapeutically effective amount of the composition of claim 1 .
9. An immunogenic composition according to claim 1 , further comprising:
a TLR-3 agonist adjuvant; and
a vesicle which comprises a non-ionic surfactant and a transport enhancer which facilitates the transport of lipid-like molecules across mucosal membranes.
10. A method of inducing an immune response in an individual, the method comprising orally administering to the individual a therapeutically effective amount of the composition of claim 9 .
11. An immunogenic composition according to claim 1 , further comprising:
a TLR-4 agonist adjuvant; and
a vesicle which comprises a non-ionic surfactant.
12. A method of inducing an immune response in an individual, the method comprising parenterally administering to the individual a therapeutically effective amount of the composition of claim 11 .
13. The composition of claim 2 , wherein each peptide is immunogenic.
14. The composition of claim 2 , wherein the composition further comprises an adjuvant.
15. The composition of claim 2 , wherein at least one peptide is associated with a vesicle.
16. The composition of claim 15 , wherein the vesicle comprises a non-ionic surfactant.
17. The composition of claim 16 , wherein the vesicle comprises a transport enhancer which facilitates the transport of lipid-like molecules across mucosal membranes.
18. An immunogenic composition according to claim 2 , further comprising:
a TLR-3 agonist adjuvant; and
a vesicle which comprises a non-ionic surfactant and a transport enhancer which facilitates the transport of lipid-like molecules across mucosal membranes.
19. An immunogenic composition according to claim 2 , further comprising:
a TLR-4 agonist adjuvant; and
a vesicle which comprises a non-ionic surfactant.
20. A method of inducing an immune response in an individual, the method comprising administering to the individual a therapeutically effective amount of the composition of claim 2 .
21. A method of inducing an immune response in an individual, the method comprising administering to the individual a therapeutically effective amount of the composition of claim 18 .
22. A method of inducing an immune response in an individual, the method comprising administering to the individual a therapeutically effective amount of the composition of claim 19 .